Session information
- Title:
- Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)
- Description:
-
Please note: This session has not been updated since it was published on 24th March 2023. Although all the information about the vaccine and its storage and administration is correct, vaccinators should refer to the Green Book COVID-19 chapter and operational guidance from NHS England for use of this vaccine in the autumn 2023 vaccination campaign.
VidPrevtyn Beta is not currently being routinely supplied but may be offered as an alternative when an mRNA vaccine is not considered clinically suitable. For this indication it is now recommended for those aged 18 years and above (VidPrevtyn Beta is licensed for individuals 18 years of age and older but its use as an alternative vaccine was previously restricted to those aged 65 years and above).
There have been no changes to the Summary of Product Characteristics (SPC) for this vaccine since it was first licensed.
This session provides specific information about VidPrevtyn® Beta (recombinant, adjuvanted) COVID-19 vaccine, common abbreviated name VidPrevtyn® Beta, manufactured by Sanofi Pasteur. It is designed to provide healthcare workers with the knowledge they need to administer this vaccine safely and effectively to eligible adults.
This session will cover key information including how the vaccine works, how it should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions. The Core knowledge session covers key areas including legal aspects of vaccination. The Core knowledge session must therefore be completed in addition to this vaccine-specific session by any individual who has not already done this. (It can also be re-visited at any time by experienced staff for the purposes of refreshing their wider knowledge.)
After completing this session about the VidPrevtyn® Beta COVID-19 vaccine, you should complete the accompanying knowledge assessment.
Note: The different types of COVID-19 vaccine have different storage, preparation and administration requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Sanofi COVID-19 Vaccine (VidPrevtyn® Beta) > Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)
- Author(s):
-
Laura Craig
Lesley McFarlane
- Created:
- 27 Mar 2023
- Last Major Update:
- 14 Sep 2023
- Keywords:
- 099-0011, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Sanofi Pasteur, VidPrevtyn, beta, recombinant, adjuvanted
- Quicklink:
- 099-0011
Share this item
- Copy URL
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.4/5
4.4/5
Self assessments
4.4/5
4.4/5
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.4/5
4.4/5
Self assessments
4.4/5
4.4/5
- Title:
- Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)
- Description:
-
Please note: This session has not been updated since it was published on 24th March 2023. Although all the information about the vaccine and its storage and administration is correct, vaccinators should refer to the Green Book COVID-19 chapter and operational guidance from NHS England for use of this vaccine in the autumn 2023 vaccination campaign.
VidPrevtyn Beta is not currently being routinely supplied but may be offered as an alternative when an mRNA vaccine is not considered clinically suitable. For this indication it is now recommended for those aged 18 years and above (VidPrevtyn Beta is licensed for individuals 18 years of age and older but its use as an alternative vaccine was previously restricted to those aged 65 years and above).
There have been no changes to the Summary of Product Characteristics (SPC) for this vaccine since it was first licensed.
This session provides specific information about VidPrevtyn® Beta (recombinant, adjuvanted) COVID-19 vaccine, common abbreviated name VidPrevtyn® Beta, manufactured by Sanofi Pasteur. It is designed to provide healthcare workers with the knowledge they need to administer this vaccine safely and effectively to eligible adults.
This session will cover key information including how the vaccine works, how it should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions. The Core knowledge session covers key areas including legal aspects of vaccination. The Core knowledge session must therefore be completed in addition to this vaccine-specific session by any individual who has not already done this. (It can also be re-visited at any time by experienced staff for the purposes of refreshing their wider knowledge.)
After completing this session about the VidPrevtyn® Beta COVID-19 vaccine, you should complete the accompanying knowledge assessment.
Note: The different types of COVID-19 vaccine have different storage, preparation and administration requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Sanofi COVID-19 Vaccine (VidPrevtyn® Beta) > Sanofi COVID-19 Vaccine (VidPrevtyn® Beta)
- Author(s):
-
Laura Craig
Lesley McFarlane
- Created:
- 27 Mar 2023
- Last Major Update:
- 14 Sep 2023
- Keywords:
- 099-0011, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Sanofi Pasteur, VidPrevtyn, beta, recombinant, adjuvanted
- Quicklink:
- 099-0011